10th ISHL Highlights
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: November 18, 2016
Expiration Date: November 18, 2017
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
There have been many advances in the treatment and management of Hodgkin lymphoma, including the practice of PET-adapted therapy, the utilization of immunotherapy and investigations into new combination therapies, such as brentuximab vedotin with various chemotherapy regimens. At the 10th International Symposium on Hodgkin Lymphoma (ISHL) in Cologne, Germany, there were a number of discussions and presentations of the latest clinical evidence related to these advances in Hodgkin lymphoma. In this activity, leading experts will provide highlights of various educational sessions and the latest clinical data presented at ISHL, giving participants the opportunity to remain up-to-date on advances in Hodgkin lymphoma.
This activity is designed for physicians, pharmacists, physician assistants, nurses, and other health care professionals who have an interest in enhancing their clinical skills in managing Hodgkin lymphoma.
Upon completion of this educational activity, participants should be able to:
- Identify the most clinically relevant and potentially impactful Hodgkin lymphoma presentations from the 10th International Symposium on Hodgkin Lymphoma (ISHL)
- Describe the clinical impact of emerging data on the future treatment and management of patients with Hodgkin lymphoma
Meeting Highlights from the 10th ISHL – Pauline Brice, MD; Paul Bröckelmann, MD; Andreas Engert, MD; Martin Hutchings, MD, PhD; Alison J. Moskowitz, MD
Instructions for Participation and Credit
This activity is eligible for credit through November 18, 2017. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Pauline Brice, MD
Hematologic Coordinator, Oncology
Saint-Louis Hospital APHP
Dr. Pauline Brice completed her medical studies in clinical hematology in Paris at Saint-Louis Hospital APHP, and Paris Diderot University, also known as Paris 7. She is the hematologic coordinator for the oncology team at Saint-Louis Hospital where she is involved in the outpatient unit and the organization of ambulatory treatments. In addition, she teaches at The European Lymphoma Institute. Since 1990, Dr. Brice worked with the GELA (which became the LYSA) for clinical research and is a clinical expert in malignant lymphomas. Her work and publications focused first on follicular lymphomas and Hodgkin lymphomas (HL) and she has participated in many academic clinical trials. This work was initially based on high-dose therapy and autotransplantation in relapsing lymphoma. Dr. Brice’s HL academic trials included many patients in EORTC/GELA with the aim to reduce radiotherapy in HL treatments. She then participated on new molecules research and recently in HL brentuximab and pembrolizumab. Dr. Brice has been principal investigator of more than 20 clinical trials, is a reviewer for Leukemia & Lymphoma, Haematologica, Journal of Clinical Oncology, Blood, and Annals of Oncology, and has written more than 150 peer-reviewed articles in publications including the Journal of Clinical Oncology and Blood. In addition, she is president of the scientific board of the lymphoma patient association France Lymphome Espoir, and a member of the European Society for Blood and Marrow Transplantation (EBMT), American Society of Hematology (ASH), and IHSLG.
Paul Bröckelmann, MD
German Hodgkin Study Group (GHSG)
Department I of Internal Medicine
University Hospital of Cologne
Dr. Paul Bröckelmann received his medical training at the University of Cologne, Germany. He completed internships in surgery at Universidad de Buenos Aires – Argentina, Internal Medicine at University Hospital of Cologne – Germany, Internal Medicine at Brighton Sussex Medical School – England, and Psychiatry at University Hospital of Cologne. In addition, he completed the Master Class of the European Hematology Association (EHA). Dr. Bröckelmann is at the Department of Internal Medicine, University Hospital of Cologne, and a trial physician with the German Hodgkin Study Group.
Andreas Engert, MD
Professor of Internal Medicine, Hematology, and Oncology
University Hospital of Cologne
Dr. Andreas Engert received his medical degree and completed his medical training at Hannover Medical School and the University Hospital of Cologne (Germany). He is a Professor of Internal Medicine, Hematology, and Oncology at University Hospital of Cologne, Germany.
Dr. Engert worked at the Imperial Cancer Research Fund and the Royal Free Hospital in London, United Kingdom, on new immunotherapeutic approaches for cancer. He returned to Cologne to focus on developing antibody-based immunotherapy for patients with malignant lymphoma which resulted in a number of experimental phase I/II clinical trials. After he finished his postdoctoral lecture qualification, he was appointed consultant and became head of staff. He then became coordinating editor of the Cochrane Hematological Malignancies Group (CHMG) and vice director of the Department for Hematology and Oncology.
Dr. Engert has published more than 400 original papers in journals such as The New England Journal of Medicine, The Lancet Oncology, Nature Genetics, Journal of Clinical Oncology, and others. He served as secretary and was elected chairman of the German Hodgkin Study Group (GHSG). He was elected as councilor to the European Hematology Association (EHA) Board of Directors and later joined the EHA Executive Board. The University of Belgrade awarded Dr. Engert an honorary doctorate. For his scientific work, he has received a number of awards including the Ludwig-Heilmeyer-Medal, the Arthur-Pappenheim Award, the Research Award of the University of Cologne, the award of the German Cancer Society, and the Paul-Martini-Prize.
Martin Hutchings, MD, PhD
Department of Hematology
The Finsen Centre, National Hospital
Copenhagen University Hospital
Dr. Martin Hutchings received his medical degree and his PhD on PET/CT in Hodgkin lymphoma at the University of Copenhagen, Denmark. He has trained in nuclear medicine, and is pursuing specialization in clinical oncology. Dr. Hutchings is a hemato-oncologist and senior consultant in the Department of Haematology, Rigshospitalet, Copenhagen University Hospital where he is responsible for treatment of lymphoma and for Denmark’s only dedicated Phase 1 unit for experimental treatment of hematological malignancies.
Dr. Hutchings is chairman of the EORTC Lymphoma Group. He leads a number of clinical and translational studies in the field of lymphoma, with an emphasis on Hodgkin lymphoma and mantle cell lymphoma, while maintaining a special scientific interest in the role of molecular imaging of malignant lymphoma. He has written numerous journal articles and book chapters and acts as supervisor for PhD students.
Alison J. Moskowitz, MD
Memorial Sloan Kettering Cancer Center
Instructor in Medicine
Weill Cornell Medical College
New York, New York
Dr. Alison Moskowitz received her medical degree from Albert Einstein College of Medicine in the Bronx. She completed her internal medicine residency and internship at Columbia University Medical Center, followed by hematology/medical oncology fellowships at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, New York City. Dr. Moskowitz is an Assistant Professor and Instructor in Medicine at Weill Cornell Medical College. In addition, she is an Assistant Attending Physician, Lymphoma Service, Hematologic Oncology Division, Department of Medicine, Memorial Hospital for Cancer and Allied Diseases, New York City.
Dr. Moskowitz is board certified in internal medicine, medical oncology, and hematology. She holds professional membership in the American Medical Association (AMA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH), where she is also an abstract reviewer. In addition, she is an ad hoc reviewer for Blood, Lancet Oncology, British Journal of Hematology, Annals of Oncology, Haematologica, Leukemia and Lymphoma, and the Journal of Clinical Oncology, among others. Dr. Moskowitz has lectured and authored/co-authored peer-reviewed articles on autologous stem cell transplantation, relapsed/refractory Hodgkin lymphoma, and T-cell lymphoma. Her primary research focus is on evaluating novel treatments for Hodgkin lymphoma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-16-130-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 16-130-046
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Pauline Brice has received honoraria related to formal advisory activities from Bristol-Myers Squibb Company. She has received grant support related to research activities as well as consultant fees from Takeda Oncology.
Dr. Paul Bröckelmann has received honoraria related to speakers’ bureau activities from Bristol-Myers Squibb Company and consultant fees from Takeda Oncology.
Dr. Andreas Engert has received honoraria as a consultant as well as grant support related to research activities from Bristol-Myers Squibb Company and Takeda Oncology.
Dr. Martin Hutchings has received honoraria as a consultant from Genentech USA, Inc. and Takeda Oncology. He has received grant support related to research activities from Celgene Corporation, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals, Inc., and Takeda Oncology.
Dr. Alison Moskowitz has received honoraria related to speakers’ bureau activities from Takeda Oncology and honoraria as a consultant from Bristol-Myers Squibb Company.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, has no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Takeda Oncology.
©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.